sternum under general anesthesia. Peripheral blood stem cells 
will also be collected by a continuous flow centrifuge in the 
Pheresis Unit. Thirty percent of the autologous marrow cells 
will be incubated with a virus which cannot cause an infection 
in the body to mark the cells with DNA molecules. This 
"marked" marrow will be added to the rest of the marrow and 
returned to the patient after intensive therapy. Patients 
will receive high doses of cyclophosphamide on day 1 to 2, VP- 
16 on day 1 to 3 by vein. The radiation will be given twice 
a day during days 6 through 8 . On day 9 , the stored bone 
marrow and peripheral blood will be given back through a vein. 
Interferon therapy will be used to maintain the state of 
normal marrow function after recovery from the transplant. 
Whenever available, patients will be treated in the sterile 
environment and receive antibiotic treatments. This is 
intended to reduce the risk of infections. The usual stay in 
this room is four to six weeks, depending upon recovery of the 
blood counts. It is estimated that 25 participants will be 
necessary in order to complete this clinical research study. 
The therapy the patient will receive during the transplant and 
in the event of relapse would be the same as if the patient 
had not had the marrow marked with the virus. 
Ten percent of the cells in the autologous marrow will be 
marked. A small amount of extra blood (one tablespoon full) 
may be required for studies after the transplant to follow the 
marking procedure, but this will not require additional 
venipunctures over and above that which is already required to 
follow your transplant recovery. 
4. RISKS, SIDE EFFECTS AND DISCOMFORTS TO PARTICIPANTS; 
Antitumor agents as well as total body irradiation treatments 
damage tumor cells as well as normal tissue. Therefore, side 
effects are likely to occur and may be life-threatening. In 
particular, bone marrow transplantation patients could require 
four to six weeks to recover white cells (necessary for 
fighting infections) or even longer to recover platelets 
(Blood cells needed to stop bleeding) . The marrow cells and 
peripheral blood cells which have been frozen will be given. 
Treatment with antibiotics and transfusion of platelets, red 
cells, and sometimes white cells, is expected. Other side 
effects include nausea and vomiting, loss of hair, mouth 
soreness, allergic reactions with a fall in blood pressure, 
skin rash, muscle aches, heart, lung, and kidney damage, 
diarrhea, and sore veins. Cyclophosphamide may cause blood in 
the urine but an agent which may protect the bladder from this 
complication, mesna, is being used. Neurological problems 
such as seizures may occur. From previous experience, death 
resulting from the toxicity of the chemotherapy and 
irradiation occurs in less than 12% of patients due to 
infections or bleeding as a result of low counts. 
4a. This clinical research may involve unforeseeable risks to 
Recombinant DNA Research, Volume 14 
[765] 
